THE LATEST:&MannKind, which has focused on the development of inhaled therapeutic products, announced in March that it is adjusting research and development resources to focus on respiratory viral infections such as Covid-19. The shift comes after the strongest quarter in company history for its inhaled insulin product Afrezza, which generated nearly $8 million in sales. Kresa in January sold for $37 million, to an unidentified party, the Beverly Hills mansion he developed.



BACKGROUND: Kresa, a former chief executive and chairman of Northrop Grumman Corp., joined MannKind's board in 2004 and was named chairman in 2016. The Westlake Village-based biopharmaceutical company develops therapeutic products for the treatment of diabetes and pulmonary arterial hypertension. Kresa is chairman of the advisory board of Lincoln Laboratory at the Massachusetts Institute of Technology, his alma mater. He is also a member of the board of overseers at Keck School of Medicine of USC and chairman emeritus of the Caltech board of trustees.



YEARS ON THE LA500: 5